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Tobramycin inhalation therapy is an effective therapy for cystic fibrosis as well as 
severe bronchiectasis that is colonized with Pseudomonas aeruginosa. The mechanism 
responsible for the efficacy of tobramycin in the treatment of severe chronic infectious 
diseases has not been elucidated. We demonstrate that high-dose tobramycin decreases 
MUC5AC gene expression and protein production in NCI-H292 cell stimulated with 
lipopolysaccharide of P. aeruginosa. MUC5AC protein of NCI-H292 cell stimulated by 
lipopolysaccharide was analyzed by an enzyme-linked immunosorbent assay and 
MUC5AC expression at the mRNA level was analyzed by RT-PCR. Westernblot was 
performed to examine a potential role for the signaling molecules upstream of NFB. 
High-dose tobramycin (500 µg/ml) decreased the level of MUC5AC protein released 
into the supernatant of the NCI-H292 cell line at 24 h after lipopolysaccharide 
stimulation (P < 0.001). The tobramycin treatment also inhibited MUC5AC mRNA 
expression at 12 h after lipopolysaccharide stimulation (P < 0.05) and suppressed 
nuclear factor-kappa B activation 60 min after lipopolysaccharide stimulation (P < 
0.001). Tobramycin suppressed the phosphorylation of p38 MAP kinase. These results 
suggest that high-dose tobramycin, such as inhalation therapy, can inhibit MUC5AC 
gene expression and MUC5AC protein production in NCI-H292 cells, in part through 
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the mitogen-activated protein kinase pathway. Thus, the activation of TLR4 and the 
subsequent immune/inflammatory responses induced by chronic infections such as P. 
aeruginosa might be modulated by tobramycin. Our data may reveal one of the 
mechanisms responsible for the clinical effect of tobramycin inhalation therapy against 












Chronic respiratory infectious diseases are difficult to treat, especially when the 
bronchial tissue is colonized and infected with Pseudomonas aeruginosa (［Eitzgerald et 
al., 1996］, ［Gibson et al., 2003］, ［Li et al., 1997］). The intermittent administration of 
inhaled tobramycin is an effective treatment for cystic fibrosis (CF) patients; 
tobramycin treatment leads to improved pulmonary function, a decreased density of P. 
aeruginosa in sputum, and a decreased risk of hospitalization (［Gibson et al., 2003］, 
［Lee et al., 2004］, ［Ramsey et al., 1999］, ［Ratjen et al., 2001］). Some authors 
reported that tobramycin inhalation therapy is also clinically effective for severe, 
non-cystic fibrosis bronchiectasis colonized with P. aeruginosa (［Bilon et al., 2006］, 
［Dal Nergo et al., 2008］, ［Dohrman et al., 1998］, ［Scheinberg et al., 2005］). It 
has been reported that tobramycin is effective because it can decrease the bacterial 
density in sputum due to its ability to directly reach the infectious source at high 
concentrations, even if the lung tissue is destroyed; another report indicates that 
tobramycin can suppress the pathogenesis of P. aeruginosa, but the details of the 
mechanism have not been elucidated (［Geller et al., 2002］, ［Husson et al., 2005］). 
Mucus secretion, which protects the host’s mucosal surfaces against pathogens, is a 
component of the innate immunity system. However, mucus hyperproduction can be a 
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risk factor for pathogenesis because excessive mucus secretion causes airway 
obstruction, impairment of gas exchange, and obstructive pneumonia. The major 
macromolecular component of mucus is mucin protein. The MUC5AC gene encodes the 
major core protein of mucin secreted from the airway surface epithelium (［Davies et al., 
1999］ , ［Gendler et al., 1995］ , ［Hovenberg et al., 1996］ ). Bacterial infection, 
especially P. aeruginosa, plays an important role in chronic respiratory infection. P. 
aeruginosa and lipopolysaccharide (LPS) stimulate mucin production (［Li et al., 1997］, 
［Dohrman et al., 1998］, ［Kaneko et al., 2003］, ［Tamaoki et al., 1997］, ［Yanagihara 
et al., 2001］ ). Toll-like receptors (TLRs) play a key role in sensing microbial 
components and inducing innate immune responses, and LPS-induced dimerization of 
TLR4 is required for activation of downstream signaling pathways (［Lee et al., 2004］, 
［Medzhitov et al., 2001］). Stimulation of TLR4 by LPS activates both myeloid 
differential factor 88 (MyD88) and Toll/interleukin-1 receptor domain-containing 
adaptor protein inducing interferon beta (TRIF)-dependent signaling pathways leading 
to activation of mitogen-activated protein (MAP) kinase and nuclear factor kappaB 
(NFB) (［Kawai et al., 2005］, ［Takeyama et al., 1999］). For patients with chronic 
respiratory infectious disease, the control of mucus overproduction is considered 
beneficial for decreasing the disease severity and improving quality of life.  
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In the present study, to confirm the clinical effect of high-dose tobramycin inhalation 
therapy, we investigated whether high-dose tobramycin can inhibit LPS-induced mucin 
secretion from airway epithelial cells activated to produce the mucin core protein, 
MUC5AC. 
 
2. Materials and methods 
2.1. Materials. We purchased LPS of P. aeruginosa serotype 10, tobramycin, and 
dexamethasone from Sigma (Tokyo, Japan) and the RPMI 1640 medium, 
penicillin-streptomycin, fetal bovine serum, and a reverse transcription (RT)-PCR 
kit from Invitrogen (Carlsbad, CA). Human porphobilinogen deaminase LightCycler 
primer set was purchased from Roche Applied Science (Heidelberg, Germany). We 
purchased mouse MUC5AC monoclonal antibody (clone 45M1) from Neo Markers 
(Fremont, CA) and goat anti-mouse horseradish peroxidase (HRP)-conjugated 
secondary antibodies from Bio-Rad (Hercules, CA). Anti- extracellular 
signal-regulated protein kinase (ERK), anti-phospho-ERK1/2, anti-c-jun N-terminal 
kinase (JNK), anti-phospho-JNK, and anti-p38 MAP kinase, anti-phospho-p38 MAP 
kinase antibodies were obtained from Cell Signaling Technology (Danvers, MA). 
PD98059, SB203580, SP600125, CAPE, which is an inhibitor of ERK, p38 MAP 
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kinase, JNK and NFB were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). 
2.2. Cell culture. The NCI-H292 epithelial cell line was obtained from the 
American Type Culture Collection (Manassas, VA) (［Imamura et al., 2004］, 
［Ishimoto et al., 2009］, ［Kim et al., 2002］). The cells were cultured in RPMI 1640 
medium with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml 
streptomycin. The cells were grown at 37°C with 5% CO2 in fully humidified air 
and were subcultured twice weekly. The cells were seeded in a 12-well plate at 5 × 
105 cells/well. When confluent, the cells were incubated in RPMI 1640 medium 
containing 0.5% fetal bovine serum for 24 h. The cells then were rinsed with 
serum-free RPMI 1640 medium and exposed to LPS. We used P. aeruginosa LPS 
for stimulating the cell line to exclude the bactericidal effect of tobramycin. For 
inhibition studies, cells were pretreated with tobramycin 30min before exposure to 
LPS. For controls, the cells were incubated with medium alone. 
2.3. RNA extraction and reverse transcription PCR. Total RNA was prepared by 
using QuickGene RNA cultured cell kit S (Fujifilm, Tokyo, Japan). After 
contaminating DNA was removed with DNase (Message Clean kit; GenHunter, 
Nashville, TN), cDNA was constructed from 1 µg total RNA by using the 
9 
SuperScript III CellDirect cDNA Synthesis Kit (Invitrogen) according to the 
manufacturer’s instructions. Sequences for the MUC5AC primers are: ATC ACC 
GAA GGC TGC TTC TGT C (sense) and GTT GAT GCT GCA CAC TGT CCA G 
(antisense) (Imamura et al., 2004). PCR was performed in a total volume of 20 μl 
containing 5 μl cDNA template, 4 μl LightCycler Taqman Master mixture (Roche 
Diagnostics, Basel, Switzerland), 0.2 μM Taqman probe, and 0.5 μM each primer. 
Thermal cycling was performed with an initial hold for 10 min at 95°C, followed by 
30 cycles of 10 s at 95°C, 10 s at 64°C. Data was analyzed by LightCycler Software 
(v3.5) in the F1 mode with a fit point calculation method. Human porphobilinogen 
deaminase controls were used to standardize the quantification of RNA samples. We 
performed four times experiments. 
2.4. ELISA. The NCI-H292 cells were incubated in a 12-well plate, and the level of 
MUC5AC protein was measured by an enzyme-linked immunosorbent assay 
(ELISA) (Kaneko et al., 2003). Briefly, the cells were washed with phosphate 
buffered saline (PBS), exposed to trypsin, and centrifuged at 600 × g at 4°C for 5 
min to form pellets. The pellets were resuspended in lysis buffer (20 mM Tris-HCl 
[pH 8.0], 133 mM NaCl, 1% NP-40, 10% glycerol). The preparation then was 
cleared by centrifugation, and the supernatant was saved as a whole-cell lysate. 
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Protein concentrations in the supernatant were measured, and equal amounts of total 
protein were incubated at 40°C in a 96-well plate until dry. The plates then were 
washed three times with PBS, blocked with 2% bovine serum albumin for 1 h at 
room temperature, and incubated with MUC5AC antibody diluted 1:100 in PBS 
containing 0.05% Tween 20 for 1 h. The wells were washed three times with 400 µl 
PBS, HRP-conjugated anti-goat immunoglobulin G diluted 1:10,000 in PBS 
containing 0.05% Tween 20 was dispensed into each well for 1 h. The plates were 
washed three times with 400 µl PBS. Color was developed with 
3,3′,5,5′-tetramethylbenzidine-peroxidase solution, and the reaction was stopped 
with 1 N H2SO4. The absorbance was read at 450 nm. We performed four times 
experiments. 
2.5. Western blot analysis and antibodies. Cells were harvested 30 min after LPS 
stimilation, washed, and homogenized at 4°C in lysis buffer (0.1% sodium dodecyl 
sulfate [SDS], 1% Igepal CA-630, and 0.5% sodium deoxycholate) and a protease 
inhibitor cocktail (Sigma, St. Louis, MO). Cell lysates (20-50 µg) were resolved by 
electrophoresis on a 12.5% polyacrylamide gel and transferred to a polyvinylidine 
difluoride membrane. After blocking the membrane in 10% FBS and 0.1% Tween 
20 in Tris-buffered saline for 1 h at room temperature, the binding were reacted 
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overnight at 4°C with primary antibodies. After hybridization with secondary 
antibodies conjugated with horseradish peroxidase, the immuno-complexes were 
visualized by using an ECL western blotting detection system (GE Healthcare, 
Chalfont St. Giles, UK). The analysis was performed by using primary antibodies 
(1:1000) to phospho-ERK 1/2, ERK 1/2, phospho-p38 MAP kinase, p38 MAP 
kinase, and phospho JNK, JNK (Cell Signaling Technology, Danvers, MA). 
2.6. NFB transcription factor assay. Nuclear extracts from cells were obtained 
by using a nuclear/cytosol fractionation kit (BioVision) according to the 
manufacturer’s protocol. Activities of NFB p50 and p65 were investigated by using 
an NFB transcription factor assay kit (Chemicon, Temecula, CA) according to the 
manufacturer’s directions (Hasegawa et al., 2006). In short, nuclear extract (10 µg 
per sample) from untreated or treated cells was added to the capture probe, a 
double-stranded biotinylated oligonucleotide containing the consensus sequence for 
binding NFB. After incubation, the sample was transferred to a streptavidin-coated 
96-well plate. After washing, the bound NFB transcription factor subunit was 
detected with a primary antibody. The plate was incubated with a secondary 
antibody, a chromogenic substrate was added to the cells, and then the absorbance of 
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each sample was determined with a microplate reader. All experiments were 
performed four times. 
2.7. Inhibition of cell signaling activity. ERK inhibitor PD98059, p38 MAP 
kinase inhibitor SB203580 and JNK inhibitor SP600125 were used at concentrations 
of 10 to 50 µM (in dimethyl sulfoxide［DMSO］ stock solution). Cells were treated 
with these inhibitors 30 min before LPS stimulation. Control cultures were treated 
with an equal volume of DMSO. All experiments were performed four times. 
2.8. Statistical analysis. All data were expressed as the mean and standard 
deviation (SD). Differences were examined for statistical significance by using the 
one-way analysis of variance for comparisons involving more than two groups and 
the Student’s t test for comparisons between two groups. P values less than 0.05 
were considered statistically significant.  
 
3. Results 
3.1. High-dose tobramycin inhibits MUC5AC protein production and mRNA 
expression induced by LPS in NCI-H292 cells. As shown in Fig. 1A, the 
MUC5AC protein production induced by LPS increased time dependently, and 
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MUC5AC production was maximal at 24h after LPS stimulation, so we performed 
the MUC5AC inhibition assay at 24 h after LPS stimulation. To determine the 
appropriate dosage of tobramycin for the inhibition of MUC5AC protein expression, 
we treated cells with tobramycin (1 to 2000 µg/ml). We used 10µg/ml 
dexamethasone as a positive control. As shown in Figure 1B, 500 µg/ml tobramycin 
was needed at least to decrease the MUC5AC protein production. We also 
performed the inhibition study of mRNA 12h after LPS stimulation because the 
level of mRNA expression was maximal 12h after LPS stimulation (data not shown). 
As shown in Figure 2, 500 μg/ml tobramycin also reduced MUC5AC expression at 
the mRNA level. Tobramycin had no inhibitory effect on the basal expression of 
MUC5AC (data not shown). Furthermore, tobramycin exposure did not significantly 
alter cell numbers and increase the lactate dehydrogenase (LDH) level of the 
supernatant. 
3.2. High-dose tobramycin inhibits NFB activation induced by LPS in 
NCI-H292 cells. The activation of NFB is an important factor in causing 
inflammation in bronchial epithelial cells. To determine whether tobramycin 
down-regulates NFB activity, we performed an assay of transcription factors. The 
activity levels of NFB p50 and p65 were increased by LPS stimulation in a 
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time-dependent manner, and they reached a maximum level 60 min after LPS 
stimulation (Figure 3A-i and ii), so we performed the inhibition assay 60 min after 
LPS stimulation. As shown in Figure 3B-i and ii, the activity levels of the NFB p50 
and p65 subunits were suppressed in tobramycin-treated NCI-H292 cells as 
compared to the LPS control cells. These results suggest that tobramycin influences 
p50 and p65 activity. 
3.3. Inhibitors of MAP kinase and NFB block LPS-induced MUC5AC 
production. To examine the cell signaling pathway of LPS via TLR4 in NCI-H292 
cells, we performed an inhibition assay of the cell signaling pathway. As shown in 
Figure 4, the NFB inhibitor CAPE, the ERK inhibitor PD98059, the p38 MAP 
kinase inhibitor SB203580, and the JNK inhibitor SP600125 effectively suppressed 
the MUC5AC protein production compared with the LPS control cells. These results 
indicate that LPS from P. aeruginosa influences MUC5AC production via the 
MAPK pathway. 
3.4. High-dose tobramycin inhibits the phosphorylation of MAP kinase in 
LPS-activated NCI-H292 cells. To examine a potential role for the signaling 
molecules upstream of NFB, we examined the phosphorylation of kinase, which is 
the extracellular signaling pathway of TLR4. Lysates of LPS-treated NCI-H292 
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cells were subjected to western blotting. As shown in Figure 5, ERK and p38 MAP 
kinase were phosphorylated in the LPS control cells and the phosphorylation of 
ERK, and p38 MAP kinase suppressed in tobramycin-treated cells. These results 
support the possibility that the inhibition of the phosphorylation of MAP kinase by 
tobramycin contributes to the suppression of MUC5AC. 
 
4. Discussion 
Chronic airway infectious diseases, such as diffuse panbronchiolitis, bronchiectasis, 
and cystic fibrosis, are characterized by mucus hypersecretion induced by inflammation 
of the airways (［Bilton et al., 2006］, ［Drobnic et al., 2005］). A large amount of 
sputum causes airway obstruction, atelectasis, reduced oxygenation, and reduced 
antibiotic permeability. MUC5AC is the major core protein of mucin secreted from 
bronchial epithelial cells. MUC5AC expression is up-regulated by inflammatory 
mediators (Takeyama et al., 2000) and cytokines (［Dabbagh et al., 1999］, ［Longphre 
et al., 1999］, ［Shim et al., 2001］). Chronic P. aeruginosa infection in the lungs often 
causes mucus overproduction. The supernatant of P. aeruginosa contains an activity 
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that up-regulates transcription of the mucin genes (Li et al., 1997), and LPS is present in 
the supernatant and can activate MUC5AC (Dohrman et al., 1998). 
In cystic fibrosis patients, P. aeruginosa has been found to grow to high concentrations 
with biofilm and intravenous antibiotics can’t reach the appropriate concentration to the 
infectious source (Singh et al., 2000), therefore, it is difficult to eradicate this organism 
from the airway. The intermittent administration of inhaled tobramycin is an effective 
treatment for cystic fibrosis patients (［Gibson et al., 2003］, ［Lee et al., 2004］, 
［Ramsey et al., 1999］, ［Ratjen et al., 2001］). Tobramycin inhalation therapy improves 
pulmonary function, decreases the density of P. aeruginosa in sputum, and decreases 
the risk of hospitalization. Recently, the efficacy of tobramycin inhalation therapy to 
non-cystic fibrosis severe bronchiectasis colonized with P. aeruginosa has been 
reported (Scheinbeg et al., 2005). We have also observed patients who had severe 
bronchiectasis with P. aeruginosa for whom tobramycin treatment decreased the 
amount of sputum and improved their quality of life; the conditions of these patients did 
not improve with other intravenous antibiotics. In addition, some authors reported the 
non bacterial effect of aminoglycoside; Anderson et al. reported the effects of 
tobramycin on P. aeruginosa biofilm on cystic fibrosis-derived airway epithelial cells in 
vitro (Anderson et al., 2008). Du et al. reported that clinical doses of amikacin provide 
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effective suppression of the human CFTR-G542X stop mutation in a transgenic cystic 
fibrosis mouse model (Du et al., 2002). In the present study, we investigated whether 
tobramycin can inhibit MUC5AC expression to elucidate the relationship between the 
clinical effect of tobramycin and MUC5AC suppression. We treated the bronchial cell 
line with a high dose of tobramycin (500 µg/ml) because the concentration of inhaled 
tobramycin can reach very high in sputum, epithelial lining fluid, and alveolar 
macrophages (［Geller et al., 2002］, ［Touw et al., 1997］). We found that tobramycin 
can control the MUC5AC expression by suppressing the MAP kinase pathway. 
Stimulation of TLR4 by LPS activates (MyD88 signaling pathways leading to the 
activation of MAP kinase. Our result suggests that the anti-inflammatory effect of 
tobramycin involves MUC5AC as well as the other stress factors associated with the 
MAPK pathway; so, tobramycin may use multiple pathways to suppress inflammation. 
The presence of sputum decreases the bioactivity of tobramycin against the bacteria 
(［Hunt et al., 1995］, ［Landy et al., 2006］), and mucin plays an important role in the 
development and function of biofilm. But, few reports have addressed the effect of 
tobramycin on host immunity. Our results suggest that tobramycin may increase the 
bactericidal effect against P. aeruginosa by decreasing the amount of sputum via the 
inhibition of MUC5AC expression. 
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A reduction in sputum causes improved lung function, improved accessibility of 
antibiotics to the small airway, and increased effects against the infection. Recently, 
aminoglycoside inhalation therapy is reported as the helpful therapy to prevent and treat 
the ventilator-associated pneumonia (VAP) (［Ghannam et al., 2009］, ［Mohr et al., 
2007］). We consider that inhaled aminoglycoside therapy may contribute to control the 
ventilator-associated infection not only by eradicating the bacteria but also by 
decreasing the amount of sputum. 
In conclusion, high-dose tobramycin inhibits the MUC5AC expression induced by P. 
aeruginosa LPS. Tobramycin seems to reduce MUC5AC production by interfering with 
intracellular signal transduction. Our results provide a possible explanation for the 
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Fig. 1. The effect of LPS on MUC5AC production in NCI-H292 cells. NCI-H292 cells were stimulated with 10 μg/ml LPS of P. 
aeruginosa. The each bar shows % above control (culture medium alone). (A) MUC5AC protein level was measured by ELISA (time 
course). Data are expressed as the mean and SD for four times experiments. (B) Cells were treated with 1, 10, 100, 500, 1000, 2000 
µg/ml tobramycin. MUC5AC protein level was measured by ELISA at 24 h after the addition of LPS. Data are expressed as the mean 
and  SD for four times experiments. *P < 0.05, **P < 0.001 compared with untreated cells (LPS alone).
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Fig. 2. MUC5AC mRNA expression at 12 h after the addition of LPS (10 µg/ml) of P. 
aeruginosa was determined by RT-PCR. Cells were pretreated with tobramycin (500 
g/ml) or dexamethasone (10 µg/ml) 30 min before LPS stimulation. The each bar 
shows % above control (culture medium alone). Data are expressed as the mean  SD 














Fig. 3. Activities of NFB p50 and p65 were investigated by using an NFB 
transcription factor assay. The each bar shows % above control (culture medium alone). 
(A) Time-dependent effect of LPS on NFB p50 (i) and p65 (ii) activation in NCI-H292 
cells. NCI-H292 cells were stimulated with 10 μg/ml LPS of P. aeruginosa. Data are 
expressed as the mean  SD for four times experiments. (B) Activities of NFB p50 (i) 
and p65 (ii) were inhibited by 500 μg/ml tobramycin. Data are expressed as the mean  
SD for four times experiments. *P < 0.05 as compared with untreated cells (LPS alone).  
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Fig. 4. Effect of MAP kinase inhibitor on MUC5AC production in cells activated by 
LPS. The each bar shows % above control (culture medium alone). Cells were 
pretreated with 50 μM PD98059, 10 μM SB203580, SP600125, and CAPE 30 min 
before LPS stimulation. Data are expressed as the mean and  SD for four times 
experiments. *P < 0.05, **P < 0.001 compared with untreated cells (LPS alone). 
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Fig. 5. Phosphorylation of ERK1/2 and p38 MAP kinase by LPS. Cells were pretreated 
with tobramycin (500 g/ml) 30 min before LPS stimulation. Cells were harvested 30 
min after LPS stimulation and evaluated by western blotting. Phosphorylation of 
ERK1/2 and p38 MAP kinase were induced in LPS-treated cells and inhibited by 
tobramycin. p, phospho; C, control (culture medium alone); U, untreated cells (LPS 
alone); T, tobramycin-treated cell. 
